CCNE2 and breast carcinoma: Although reported to be undetectable in non-transformed cells [7], overexpression of cyclin E2 in breast cancer cells has been found to be associated with increased resistance to both chemotherapy and endocrine therapy [8, 9], and thus cyclin E2 has been included in the gene expression pattern that predict poor prognosis in endocrine-resistant and metastatic breast cancers.